1. The Committee of Brain Tumor Registry of Japan . Report of Brain Tumor Registry of Japan (1969-1996), 11 th Edition, Neurolgia Medico-Chirurugica, 43 (Supplement) ( Tokyo ): The Japan Neurological Society; 2003.

2. Hulshof MC, Koot RW, Schimmel EC, et al. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution. Strahlenther Onkol. 2001;177:283-90.

3. Lacroix M, Abi-Said D, Fourney DR , et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-198.

4. Prados MD, Larson DA, Lamborn K, et al. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys. 1998;40:57-63.

5. Shrieve DC, Alexander E 3rd, Black PM, et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg. 1999;90:72-7.

6. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980 303:1323-9.

7. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47:649-52.

8. Glioma Meta-analysis Trialists (GMT) Group (Stewart LA): Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359(9311):1011-1018.

9. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.

10. Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin. Cancer Res. 2003 ; 9:3294-3302 .

11. Tsurushima H, Liu SQ, Tsuboi K, et al. Reduction of end-stage malignanat glioma by injection with autologous cytotoxic T lymphocytes. Jpn. J. Cancer Res. 1999;90: 536-545.

12. Ohno T. Autologous Cancer Vaccine: A Novel Formulation. Microbiol. Immunol., 2003;47: 255-263.

13. Peng BG, Liu SQ, Kuang M, et al. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res. 2002;93:363-368.

14. Liu SQ, Saijo K, Todoroki T, et al. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat Med. 1995;1:267-271.

15. Liu SQ, Shiraiwa H, Kawai K, et al. Tumor-specific autologous cytotoxic T lymphocytes from tissue sections. Nat Med. 1996;2:1283.

16. Kim C, Matsumura M, Saijo K, et al. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother. 1998;47:90-96.

17. Ishikawa E, Tsuboi K, Takano S, et al. Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of an intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model. Cancer Sci. 2004;95:98-103.

18. Kuang M, Peng BG, Lu MD, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004;10:1574-1579.